Five-year overall survival (OS) and OS by baseline liver function from the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

被引：0
|
作者：
Kudo, M. [1 ]
Rimassa, L. [2 ]
Chan, S. L. [3 ]
Sangro, B. [4 ,5 ,6 ]
Lau, G. [7 ]
Breder, V. V. [8 ]
Varela, M. [9 ]
Crysler, O. V. [10 ]
Bouattour, M. [11 ]
Dao, V. T. [12 ]
Faccio, A. [13 ]
Furuse, J. [14 ]
Jeng, L-B. [15 ]
Kang, Y-K. [16 ]
Kelley, R. K. [17 ]
Paskow, M. J. [18 ]
Makowsky, M. [19 ]
Ran, D. [20 ]
Negro, A. [19 ]
Abou-Alfa, G. K. [21 ,22 ]
机构：
[1] Kindai Univ, Fac Med, Dept Gastroenterol & Hepatol, Osaka, Japan
[2] Humanitas Univ, Pieve Emanuele & Humanitas Canc Ctr, IRCCS Humanitas Res Hosp, Dept Biomed Sci, Milan, Italy
[3] Chinese Univ Hong Kong, State Key Lab Translat Oncol, Dept Clin Oncol, Sir Yue Kong Pao Ctr Canc, Hong Kong, Peoples R China
[4] Clin Univ Navarra, Liver Unit, Pamplona, Spain
[5] Clin Univ Navarra, HPB Oncol Area, Pamplona, Spain
[6] CIBEREHD, Pamplona, Spain
[7] Humanity & Hlth Med Grp, Humanity & Hlth Clin Trial Ctr, Hong Kong, Peoples R China
[8] NN Blokhin Natl Med Res Ctr Oncol, Dept Chemotherapy, Moscow, Russia
[9] Univ Oviedo, Liver Unit, Hosp Univ Cent Asturias, IUOPA,ISPA,FINBA, Oviedo, Spain
[10] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI USA
[11] Hop Beaujon, AP HP, Liver Canc Unit, Paris, France
[12] Natl Canc Hosp, Canc Res & Clin Trials Ctr, Dept Optimal Therapy, Hanoi, Vietnam
[13] CEON Ctr Especializado Oncol, Dept Oncol, Ribeirao Preto, Brazil
[14] Kanagawa Canc Ctr, Dept Gastroenterol, Tokyo, Japan
[15] China Med Univ & Hosp, Dept Surg, Taichung, Taiwan
[16] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[17] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
[18] AstraZeneca, Global Med Affairs, Gaithersburg, MD USA
[19] AstraZeneca, Oncol R&D, Late Stage Dev, Gaithersburg, MD USA
[20] AstraZeneca, Stat, Gaithersburg, MD USA
[21] Cornell Univ, Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
[22] Cornell Univ, Weill Med Coll, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.151
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1270
引用
收藏
页码：S1451 / S1452
页数：3
相关论文
共 50 条
  • [41] Impact of baseline liver function on survival outcomes in patients with unresectable hepatocellular carcinoma (uHCC) treated with camrelizumab plus rivoceranib vs sorafenib: A post hoc analysis of study CARES-310.
    Vogel, Arndt
    Cheng, Ann-Lii
    Shi, Wei
    Jang, Seong
    Alexander, Laura
    Meng, Xianzhang
    Raphael, Natalia
    Chan, Stephen Lam
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 509 - 509
  • [42] Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)
    Oh, D-Y.
    He, A. R.
    Qin, S.
    Chen, L-T.
    Okusaka, T.
    Vogel, A.
    Kim, J. W.
    Lee, T.
    Lee, M. A.
    Kitano, M.
    Burris, H. A.
    Bouattour, M.
    Tanasanvimon, S.
    Zaucha, R. E.
    Avallone, A.
    Cundom, J. E.
    Rokutanda, N.
    Zotkiewicz, M.
    Cohen, G.
    Valle, J. W.
    ANNALS OF ONCOLOGY, 2022, 33 : S1462 - S1463
  • [43] Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin ( plus GC) in patients (pts) with advanced biliary tract cancer (BTC)
    Oh, D. Y.
    He, A. R.
    Qin, S.
    Chen, L. T.
    Okusaka, T.
    Vogel, A.
    Kim, J. W.
    Suksombooncharoen, T.
    Lee, M. A.
    Kitano, M.
    Burris, H. A.
    Bouattour, M.
    Tanasanvimon, S.
    Zaucha, R. E.
    Avallone, A.
    Cundom, J. E.
    Rokutanda, N.
    Watras, M.
    Cohen, G.
    Valle, J. W.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S565 - S566
  • [44] Impact of baseline liver function on overall survival (OS) and safety in patients ( pts) with unresectable hepatocellular carcinoma (HCC) treated with first-line (1L) tislelizumab (TIS): results from the RATIONALE-301 study
    Kudo, Masatoshi
    Vogel, Arndt
    Meyer, Tim
    Boisserie, Frederic
    Li, Songzi
    Abdrashitov, Ramil
    Chen, Yaxi
    Zhu, Andrew X.
    Qin, Shukui
    Finn, Richard S.
    JOURNAL OF HEPATOLOGY, 2023, 78 : S574 - S574
  • [45] PD-L1 as a predictor of survival in patients with metastatic urothelial carcinoma (mUC) from the phase III DANUBE trial of durvalumab (D) or durvalumab plus tremelimumab (D plus T) versus standard of care chemotherapy (SoC)
    Bellmunt, J.
    Powles, T. B.
    Van der Heijden, M. S.
    Galsky, M. D.
    He, P.
    Wang, Z.
    Xiao, F.
    Jones, F.
    Scott, M.
    Walker, J.
    Angra, N.
    Gupta, A.
    Drakaki, A.
    Kimura, G.
    Mizokami, A.
    Wildsmith, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S716 - S717
  • [46] IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
    Finn, Richard S.
    Qin Shukui
    Ikeda, Masafumi
    Galle, Peter R.
    Ducreux, Michel
    Kim, Tae-You
    Lim, Ho Yeong
    Kudo, Masatoshi
    Breder, Valeriy Vladimirovich
    Merle, Philippe
    Kaseb, Ahmed Omar
    Li Daneng
    Verret, Wendy
    Shao Hui
    Liu Juan
    Li Lindong
    Zhu, Andrew X.
    Chen, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [47] IMbrave150: updated overall survival (OS) data from a global, randomized, open-label Phase III study of atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
    Galle, P.
    Finn, R. S.
    Qin, S.
    Ikeda, M.
    Ducreux, M.
    Kim, T. -Y
    Lim, H. Y.
    Kudo, M.
    Breder, V
    Merle, P.
    Kaseb, A.
    Li, D.
    Verret, W.
    Shao, H.
    Liu, J.
    Li, L.
    Zhu, A. X.
    Cheng, A. -L
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 34 - 34
  • [48] Updated overall survival (OS) data from the phase 1b study of tebentafusp (tebe) as monotherapy or combination therapy with durvalumab (durva) and/or tremelimumab (treme) in metastatic cutaneous melanoma (mCM).
    Middleton, Mark R.
    Hamid, Omid
    Shoushtari, Alexander Noor
    Meier, Friedegund Elke
    Bauer, Todd Michael
    Salama, April K. S.
    Kirkwood, John M.
    Ascierto, Paolo Antonio
    Lorigan, Paul
    Mauch, Cornelia
    Orloff, Marlana M.
    Evans, T. R. Jeffry
    Abdullah, Shaad Essa
    Yuan, Yuan
    Mitchell, James
    Hassel, Jessica Cecile
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [49] Durvalumab (D) ± tremelimumab (T) plus chemotherapy (CT) in 1L metastatic (m) NSCLC: Overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y)
    Johnson, M.
    Cho, B. C.
    Luft, A.
    Alatorre-Alexander, J.
    Geater, S. L.
    Laktionov, K.
    Kim, S-W.
    Ursol, G.
    Hussein, M.
    Lim, F. L.
    Yang, C. T.
    Araujo, L. H.
    Saito, H.
    Reinmuth, N.
    Lai, Z.
    Mann, H.
    Shi, X.
    Peters, S.
    Garon, E.
    Mok, T. S. K.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1424 - S1425
  • [50] Baseline covariates impacting overall survival (OS) in a phase III study of men with bone metastases from castration-resistant prostate cancer.
    Fizazi, Karim
    Massard, Christophe
    Smith, Matthew Raymond
    Rader, Michael E.
    Brown, Janet Elizabeth
    Milecki, Piotr
    Shore, Neal D.
    Oudard, Stephane
    Karsh, Lawrence Ivan
    Carducci, Michael Anthony
    Damiao, Ronaldo
    Wang, Huei
    Goessl, Carsten Dietrich
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345